CeQur, a developer of wearable delivery devices, has started a clinical study of PaQ insulin delivery device.
The PaQ study is conducted by Thomas Pieber, head of endocrinology and metabolism division at Austria University Hospital.
The study is designed to evaluate that individuals with type 2 diabetes can successfully use PaQ to deliver their daily insulin..
Study endpoints include glycemic control, patient satisfaction and safety.
The company said the initial results are expected to be released in early 2012.
PaQ features a disposable insulin infuser reservoir, attached to a reusable insulin monitor, and is designed to provide three days of consistent, basal insulin delivery along with easy, on-demand bolus insulin.
Austria University Hospital endocrinology and metabolism division head Thomas Pieber said, "There is a tremendous need for technologies such as PaQ that make insulin administration more comfortable, simple and convenient for patients, so that they are able to maintain better control of their disease and, therefore, their health."
